GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging ...

P liant Therapeutics has reported interim results from its ongoing Phase I dose escalation trial of PLN-101095, along with ...

AINMF READ THE FULL AINMF RESEARCH REPORT Company’s AI technology designed to help optimize drug development clinical trial outcomes… NetraMark (OTCQB:AINMF) is an Artificial Intelligence (AI) company ...

AI-driven discovery, EHR-based real-world evidence, and synthetic patient modeling are rapidly reshaping drug repurposing, reducing development timelines, expanding therapeutic applications, and ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

VectorY Therapeutics receives US FDA clearance to proceed with PIONEER-ALS phase 1/2 clinical trial of VTx-002: Amsterdam Friday, December 5, 2025, 18:00 Hrs [IST] VectorY Therape ...

Commissioner Marty Makary said that the FDA will soon start requiring only one pivotal trial, instead of two, for companies ...

TransThera Sciences Inc. ('TransThera') announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet ...

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes ...

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire ...

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...